DYNE THERAPEUTICS INC's ticker is DYN and the CUSIP is 26818M108. A total of 103 filers reported holding DYNE THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $511,332 | -90.1% | 18,011 | -95.4% | 0.00% | -100.0% |
| Q4 2023 | $5,161,597 | +235266.9% | 388,090 | +103.9% | 0.00% | +100.0% |
| Q1 2023 | $2,193 | -25.5% | 190,363 | -25.1% | 0.00% | -50.0% |
| Q4 2022 | $2,945 | -99.7% | 254,110 | +210.1% | 0.00% | +100.0% |
| Q3 2022 | $1,041,000 | +28.5% | 81,951 | +112.4% | 0.00% | 0.0% |
| Q4 2020 | $810,000 | -79.3% | 38,590 | -80.1% | 0.00% | -80.0% |
| Q3 2020 | $3,918,000 | – | 194,065 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vida Ventures Advisors, LLC | 2,220,034 | $25,574,792 | 34.99% |
| MPM ASSET MANAGEMENT LLC | 4,951,303 | $57,039,011 | 23.77% |
| Atlas Venture Life Science Advisors, LLC | 9,885,449 | $113,880,372 | 15.42% |
| TCG Crossover Management, LLC | 1,650,150 | $19,009,728 | 3.70% |
| Logos Global Management LP | 1,700,000 | $19,584,000 | 2.80% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 433,751 | $4,988,137 | 1.39% |
| Octagon Capital Advisors LP | 692,945 | $7,982,726 | 1.15% |
| Deep Track Capital, LP | 2,334,633 | $26,894,972 | 1.10% |
| Altium Capital Management LP | 155,000 | $1,785,600 | 0.99% |
| HighVista Strategies LLC | 102,431 | $1,180,005 | 0.96% |